to Prevent Progressive Ocular Disease
Vision loss is a rapidly growing cause of disability, globally affecting all age groups, from the premature infant to age-related conditions. Progressive corneal conditions may lead to irreversible scarring with vision loss. Progressive retinal conditions cause loss of retinal neurons, including ganglion cells and sensory cells and, once lost, cannot be replaced.
Neuroprotectin D1 (NPD1), the eye’s most powerful protective homeostatic regulator, is an evolutionary adaption to protect the eye during normal conditions.
NPD1 is a highly potent lipid derived small molecule agonist. Activating multiple regulatory pathways aimed at tissue protection NPD1 has the therapeutic advantage of targeting pathological redundancy.
Anida is developing AP-001, a slightly modified version of NPD1. AP-001 shows excellent therapeutic activity in established translational models of corneal and retinal disease and ocular tissue distribution supporting its development as eye drop for both corneal and retinal indications.
Therapeutic eye drop delivery is currently limited to corneal disease but requires frequent administration due to rapid drug elimination in the eye. The need of repeat administration together with limited drug distribution to the back of the eye has prevented development of eye drops as an effective route to treat retinal conditions.